Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study of ALA-3000, Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy in Subjects With Treatment-Resistant Depression (TRD)

NCT06965569 is registered in ClinicalTrials.gov with Alar Pharmaceuticals Inc. as lead sponsor.

NCT NCT06965569
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06965569 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study of ALA-3000, Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy in Subjects With Treatment-Resistant Depression (TRD)
Lead sponsor
Alar Pharmaceuticals Inc.
Phase
Phase 1
Overall status
Completed
Start date
April 21, 2025
Completion date
December 30, 2025
Enrollment
37 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

treatment resistant depression